小剂量奥氮平联合帕罗西汀治疗重性抑郁症急性期的疗效观察

Observation on the Therapeutic Effect of Low-dose Olanzapine Combined with Paroxetine in the Acute Phase of Severe Depression

目的探讨小剂量奥氮平联合帕罗西汀治疗重度抑郁症急性期的临床疗效。方法将2022年1月~2023年10月77例重度抑郁症急性期患者根据数字表随机分组,其中对照组38例服用帕罗西汀,观察组39例联合服用小剂量奥氮平。比较治疗前后焦虑抑郁情绪、血清标志物,比较治疗期间不良反应情况。结果2组治疗后相较于治疗前汉密尔顿焦虑/抑郁量表评分均下降,但治疗后观察组两项评分均更低(P<0.05);2组治疗后相较于治疗前血清5-羟色胺、多巴胺水平均上升,但治疗后观察组两项标志物水平均更高(P<0.05);治疗2周、4周、8周时两组副反应量表评分差异不显著(P>0.05)。结论小剂量奥氮平联合帕罗西汀治疗重度抑郁症急性期疗效更佳,并且并未明显增加药物不良反应。

Objective To explore the clinical efficacy of low-dose olanzapine combined with paroxetine in the treatment of severe depression in the acute phase.Methods 77 patients with severe depression in the acute phase from January 2022 to October 2023 were randomly grouped according to the numerical table.Among them,38 cases in the control group were treated with paroxetine,while 39 cases in the observation group were treated with low-dose olanzapine in combination.The anxiety,depression,emotions,and serum markers before and after treatment were compared.The adverse reactions during treatment were compared.Results After treatment,the Hamilton Anxiety/Depression Scale decreased in both groups compared to before treatment,but the observation group had lower scores in both items after treatment(P<0.05).After treatment,the serum levels of 5-hydroxytryptamine and dopamine increased in both groups compared to before treatment.However,the average water levels of the two biomarkers in the observation group were higher after treatment(P<0.05).At 2,4,and 8 weeks of treatment,there was no significant difference in the scores of the side reaction scales between the two groups(P>0.05).Conclusion The combination of low-dose olanzapine and paroxetine has a better therapeutic effect in the acute phase of severe depression,and does not significantly increase drug adverse reactions.